Juno Therapeutics Garners $134,000,000 Series B Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9a6a8334-9bd6-4497-af77-89b87dd4acf5
Date
8/5/2014
Company Name
Juno Therapeutics
Mailing Address
307 Westlake Avenue North Seattle, WA 98109 USA
Company Description
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Website
http://www.junotherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$134,000,000
Transaction Round
Series B
Proceeds Purposes
Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies.
M&A Terms
Venture Investor
Venture Investor
Venture Investor